Physician profile
Steven Farbowitz
NPI 1659326353
$1,779.50
in general payments reported to CMS, 2019-2025
25 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $103 · 2021: $171 · 2022: $213 · 2023: $281 · 2024: $373 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $419.00 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $153.32 | 2019-2021 | |
| Novo Nordisk INC | $149.03 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $146.83 | 2022-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $145.19 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $124.44 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $88.37 | 2022-2025 | Mounjaro |
| Mylan Specialty L.P. | $83.27 | 2019 | |
| Astellas Pharma US INC | $58.65 | 2023-2024 | Myrbetriq, Veozah |
| Amgen INC. | $52.50 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $43.02 | 2023-2025 | |
| Esperion Therapeutics, INC. | $41.56 | 2021 | |
| Exact Sciences Corporation | $40.38 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Avvisto Therapeutics, LLC | $37.85 | 2024-2025 | Cycloset |
| Corcept Therapeutics | $23.64 | 2025 | Korlym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $22.01 | 2019 | |
| Viiv Healthcare Company | $21.13 | 2024 | Apretude |
| Boston Scientific Corporation | $20.17 | 2025 | Watchman Flx |
| Abbvie INC. | $18.03 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.37 | 2022 | |
| Almatica Pharma LLC | $17.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.60 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Farbowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.